Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 May 21:23:e935362.
doi: 10.12659/AJCR.935362.

Cyclosporine A-Induced Conchal Hyperplasia with Nasal Obstruction in a Patient with Membranous Nephropathy

Affiliations
Case Reports

Cyclosporine A-Induced Conchal Hyperplasia with Nasal Obstruction in a Patient with Membranous Nephropathy

Frank-Peter Tillmann et al. Am J Case Rep. .

Abstract

BACKGROUND The immunomodulatory and pharmacokinetic effects of cyclosporine A are used to treat diverse disease entities in different medical fields, including organ transplantation and/or autoimmune diseases. It is also applied in patients with nephrotic range proteinuria as an adjunct to steroids and supportive antihypertensive/antiproteinuric medications. Cyclosporine has a small therapeutic window and is dosed with respect to the underlying disease entity and severity via trough level adaptations. Among its most frequent adverse effects are hypertension, nephrotoxicity, neurotoxicity, and electrolyte disturbances. Hypertrichosis and gingival hyperplasia are obvious and widely recognized adverse effects. CASE REPORT We report on a 66-year-old woman who was treated with cyclosporine A for primary membranous nephropathy. During treatment with cyclosporine, she developed hirsutism and gingival hyperplasia. Later, she reported having impaired nasal breathing and dyspnea on mild physical exercise. Clinical, rhinoscopic, and radiological evaluations showed marked conchal hyperplasia as a potential cause of her symptoms. An extensive medical work-up did not show evidence of allergic, immunologic, or other drug adverse effects, suggesting cyclosporine-induced hyperplasia of the turbinates as a hypothetical causative factor. Dose reductions did not lead to resolution of symptoms but resulted in increasing proteinuria. Therefore, cyclosporine was stopped, and the patient was treated with rituximab. Thereafter, hirsutism and gingival and conchal hyperplasia gradually regressed over 2-4 months, showing complete resolution of conchal hyperplasia on computed-tomography follow-up after 6 months. CONCLUSIONS Cyclosporine can not only result in gingival hyperplasia but also in hyperplasia of the turbinates leading to impaired nasal breathing and shortness of breath on exertion. An extensive search for many other known causes of conchal swelling is warranted to finally suggest an adverse effect of cyclosporine. Discontinuation of cyclosporine resulted in complete remission of conchal hyperplasia as well as other adverse effects.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared

Figures

Figure 1.
Figure 1.
A 66-year-old female patient with gingival hyperplasia due to cyclosporine A medication as part of a multi-drug regimen for membranous nephropathy.
Figure 2.
Figure 2.
CT scan under cyclosporine A medication showing hyperplastic turbinates of 3.7 mm.
Figure 3.
Figure 3.
CT scan under cyclosporine A medication showing hyperplastic turbinates of 4.2 mm.
Figure 4.
Figure 4.
CT scan showing regression of hyperplasia 6 months after discontinuation of cyclosporine A. The diameter at a corresponding anatomical location as compared to the baseline scan was 2.6 mm.
Figure 5.
Figure 5.
CT scan showing regression of hyperplasia 6 months after discontinuation of cyclosporin A. The diameter at a corresponding anatomical location as compared to the baseline scan was 2.8 mm.

References

    1. Patocka J, Nepovimova E, Kuca K, Wu W. Cyclosporine A: Chemistry and toxicity – a review. Curr Med Chem. 2021;28:3925–34. - PubMed
    1. Borel JF, Feurer C, Gubler HU, Stahelin H. Biological effects of cyclosporine A: a new antilymphocytic agent. Agents Actions. 1976;6:468–75. - PubMed
    1. Farouk SS, Rein JL. The many faces of calcineurin inhibitor toxicity – what the FK? Adv Chronic Kidney Dis. 2020;27:56–66. - PMC - PubMed
    1. Gandhi M, Rai E, Shirley A, Suda NK. Massive gingival bleed: A rare manifestation of cyclosporine toxicity. BMJ Case Rep. 2020;13:e236828. - PMC - PubMed
    1. Aral CA, Dilber E, Aral K, et al. Management of cyclosporine and nifedipineinduced gingival hyperplasia. J Clin Diagn Res. 2015;9:ZD12-15. - PMC - PubMed

Publication types

MeSH terms